Literature DB >> 15083945

Paroxetine use throughout pregnancy: does it pose any risk to the neonate?

I Morag1, D Batash, R Keidar, M Bulkowstein, E Heyman.   

Abstract

A newborn of a SSRI-treated mother presented with lethargy, no crying, and no response to tactile stimulation. EEG findings were abnormal. Laboratory and clinical evaluations were normal. He recovered at the age of two weeks. Serotonin is a neurotransmitter that has an important roll in pain modulation during fetal neurodevelopment. We suspect these symptoms are attributed to the intrauterine exposure to paroxetine, through modulation of pain signals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15083945     DOI: 10.1081/clt-120028753

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  4 in total

Review 1.  Serotonin reuptake inhibitor-induced perinatal complications.

Authors:  Salvatore Gentile
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 2.  The safety of newer antidepressants in pregnancy and breastfeeding.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Early-life exposure to selective serotonin reuptake inhibitors: Long-term effects on pain and affective comorbidities.

Authors:  Mathilde Baudat; Anne R de Kort; Daniel L A van den Hove; Elbert A Joosten
Journal:  Eur J Neurosci       Date:  2021-12-16       Impact factor: 3.698

4.  Pregnancy and delivery while receiving vagus nerve stimulation for the treatment of major depression: a case report.

Authors:  Mustafa M Husain; Diane Stegman; Kenneth Trevino
Journal:  Ann Gen Psychiatry       Date:  2005-09-16       Impact factor: 3.455

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.